To explore the efficacy of ivabradine in patients with acute myocardial infarction (AMI)complicated with heart failure (HF) and its influence on cardiac function and inflammatory factors.
A total of 240 patients with AMI combined with HF who were admitted to our hospital from January 2022 to January 2024 were selected and randomly divided into the observation group and the control group, with 120 cases in each group. The control group was given conventional treatment, while the observation group was treated with ivabradine tablets in addition. Both groups were treated continuously for 10 weeks. The clinical efficacy, left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), mean pulmonary artery pressure (MPAP), central venous pressure (CVP), pulmonary vascular resistance (PVR), soluble suppression of tumorigenicity 2 protein (sST2), troponin (cTn)Ⅰ, N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-α, interleukin (IL)-6 and adverse reactions were compared between the two groups.
After treatment, the total effective rate of the observation group was 90.00%, significantly higher than 78.33% of the control group (P<0.05). The LVEF of the observation group was higher than that of the control group, while LVEDD and LVESD were lower than those of the control group. The differences were all statistically significant (P<0.05). The MPAP, CVP and PVR in the observation group were all lower than those in the control group, and the differences were statistically significant (P<0.05). The levels of serum sST2, cTnⅠ and NT-proBNP in the observation group were all lower than those in the control group, and the differences were statistically significant (P<0.05). The levels of serum hs-CRP, TNF-α and IL-6 in the observation group were all lower than those in the control group, and the differences were statistically significant (P<0.05). There was no statistically significant difference in the comparison of adverse reactions between the two groups (P>0.05).
Ivabradine is helpful to improve the therapeutic effect of AMI combined with HF, and has good safety. It is worthy of clinical promotion.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |